Combining Regorafenib and TAS102 to Target Gastrointestinal Cancers and Overcome Cancer Stemness
Oncotarget Impact Journal,
https://doi.org/10.18632/oncotarget.28602The post Combining Regorafenib and TAS102 to Target Gastrointestinal Cancers and…
https://doi.org/10.18632/oncotarget.28602The post Combining Regorafenib and TAS102 to Target Gastrointestinal Cancers and…
In this research paper, researchers demonstrate a promising new treatment option for refractory metastatic gastrointestinal…
In this research paper, researchers demonstrate a promising new treatment option for refractory metastatic gastrointestinal…
https://doi.org/10.18632/oncotarget.28602The post Regorafenib Synergizes With TAS102 Against Multiple Gastrointestinal Cancers…
PRESS RELEASE: On July 2, 2024, a new research paper was published in Oncotarget, entitled, “Regorafenib synergizes with TAS102…
a biotech fraudster indicted, a Swedish rector can't stop papermilling, Oncotarget's chief editor maliciously targeted, PLOS…